Antitumor effect of combination of paclitaxel to a lipid nanoemulsão that binds to receptors of low-density lipoprotein (LDL), in human pancreatic adenocarcinoma derived lineages

• Grant number: 14/12064-6
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2014
• End date: June 30, 2015
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Carmen Guilherme Christiano de Matos Vinagre
• Grantee: Caroline Grillette Negri
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Pancreatic adenocarcinoma is one of the types of human cancer, more lethal and remains the fourth cause of death from cancer and the second between malignant diseases of the gastrointestinal tract in the United States. Your highly aggressive nature and little specific symptoms lead to late diagnosis and the resistance to chemotherapy and radiotherapy are available. Noting that some lineages of neoplastic cells express a greater number of low-density lipoprotein receptors (LDL), several studies have shown that artificial lipid nanoparticles to bind LDL receptors may be used as carriers of chemotherapeutic drugs in various types of neoplasms. With this, the treatment could be more targeted sparing the normal tissue. The objective of the present study is to evaluate the Antitumor effect of the Association nanoemulsão-paclitaxel in cell lines derived from human pancreatic adenocarcinoma. For this purpose, will be used for cellular proliferation and apoptosis: inhibitory concentration (IC50) and inhibitory capacity of cell proliferation, cell proliferation and viability test and determination of cell viability by MTT assay (3-(4.5-dimetiltiazol-2yl)-diphenyl -2.5 tetrazolina bromide).